Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma A/S (Nasdaq: ASND) announced its upcoming virtual Oncology R&D Day on November 20, 2020, at 12:00 p.m. ET. The event will showcase the application of its innovative TransCon™ technology platform to oncology, highlighting the company’s strategy and developments in creating new cancer therapies. Key focuses include updates on TransCon TLR7/8 Agonist and TransCon IL-2 β/γ programs, which aim to activate immune responses in cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-event.
Ascendis Pharma announced the validation of its Marketing Authorisation Application (MAA) for TransCon hGH (lonapegsomatropin) in pediatric growth hormone deficiency by the European Medicines Agency (EMA). The company has also submitted regulatory filings for the phase 3 PaTHway Trial of TransCon PTH in Europe and Canada, and initiated a phase 2 trial for TransCon CNP in collaboration with VISEN Pharmaceuticals. Ascendis reported a net loss of €121.7 million for Q3 2020, with revenues increasing to €2.8 million. Cash reserves stand at €957.5 million as of September 30, 2020.
Ascendis Pharma A/S (Nasdaq: ASND) has appointed Mark A. Bach, M.D., Ph.D., as Senior Vice President of Clinical Development and Medical Affairs focusing on endocrine rare diseases. His extensive experience in clinical research and development is expected to bolster the company's investigational product pipeline, particularly as it prepares for the potential launch of its first product targeting pediatric growth hormone deficiency. The company utilizes its proprietary TransCon technology to develop innovative therapies aimed at unmet medical needs in endocrinology.
Ascendis Pharma A/S (Nasdaq: ASND) will hold a conference call on November 11, 2020, at 4:30 p.m. ET to discuss its Q3 2020 financial results and provide a business update. Interested parties can dial in using 844-290-3904 (U.S.) or 574-990-1036 (international) with access code 8955314. The call will be available via webcast on their website, with a replay accessible for 30 days thereafter. Ascendis aims to leverage its innovative TransCon technologies to advance in endocrinology and oncology.
Ascendis Pharma A/S (Nasdaq: ASND) announced that the European Commission has granted Orphan Designation to its investigational drug, TransCon PTH, for treating hypoparathyroidism. This long-acting prodrug aims to normalize parathyroid hormone levels, addressing both short-term and long-term symptoms of the condition. Currently, patients are treated with calcium and vitamin D supplements, which are insufficient. The Orphan Designation enhances market exclusivity and reimbursement prospects for the drug, which has also received similar recognition from the U.S. FDA.
Ascendis Pharma A/S (Nasdaq: ASND) announced five presentations highlighting its endocrinology rare disease programs at two online medical conferences: ECTS 2020 (October 22-24) and PENS (November 2-5). Key data includes phase 2 results of TransCon PTH for hypoparathyroidism and phase 3 fliGHt Trial outcomes for TransCon hGH in pediatric growth hormone deficiency. The company aims to enhance clinical outcomes and quality of life for patients. The presentations will showcase a novel auto-injector and research on achondroplasia's impact on children.
Ascendis Pharma A/S (Nasdaq: ASND) has filed a Clinical Trial Notification with Japan's PMDA to initiate the phase 3 riGHt Trial for TransCon™ hGH, targeting pediatric growth hormone deficiency (GHD). This trial is significant as it aims to compare the height velocity of treated Japanese children against a daily hGH formulation, enhancing the product's global reach. The trial involves 40 treatment-naïve children and is expected to support marketing applications in Japan, crucial for expanding Ascendis' product offerings.
Ascendis Pharma A/S (Nasdaq: ASND) has launched the #Together4Growth campaign to raise awareness about children's growth disorders during Children’s Growth Awareness Week, from September 13-19, 2020. This initiative includes a four-question Growth Quiz for parents to identify symptoms and encourages discussion with healthcare professionals. The campaign emphasizes the importance of monitoring growth patterns and will culminate in International Children’s Growth Awareness Day on September 20, 2020. Ascendis Pharma aims to improve life quality for affected children through education and resources.
Ascendis Pharma A/S (Nasdaq: ASND) announced participation in the 18th Annual Morgan Stanley Virtual Global Healthcare Conference, scheduled for September 17, 2020, at 3:30 p.m. Eastern Time. Executives will provide a business overview and update on pipeline programs. The presentation will be accessible via live webcast on the company’s website, with a replay available for 30 days. Ascendis Pharma focuses on developing innovative therapies using its TransCon technologies, with an ongoing pipeline in endocrinology rare diseases and a budding interest in oncology.
Ascendis Pharma A/S (Nasdaq: ASND) announced three presentations for its TransCon PTH program at the ASBMR 2020 Annual Meeting, highlighting a significant phase 2 trial showing that TransCon PTH eliminated standard vitamin D treatment in 82% of participants. This investigational treatment aims to address hypoparathyroidism symptoms effectively. Additionally, a survey revealed that over two-thirds of HP patients experience calcium crashes, demonstrating the need for better treatment options. The meeting runs from September 11-15, with key presentations scheduled for September 15.